Chapter 13 : Molecular and Clinical Evaluation of Atypical Hemolytic Uremic Syndrome

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Molecular and Clinical Evaluation of Atypical Hemolytic Uremic Syndrome, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap13-1.gif /docserver/preview/fulltext/10.1128/9781555815905/9781555813642_Chap13-2.gif


Familial hemolytic uremic syndrome (HUS) was first described in 1956; both autosomal dominant and recessive forms of inheritance have been reported. The chapter discusses three pieces of evidence which suggested that complement genes apart from the gene for factor H were involved in the pathogenesis of atypical HUS. Structurally, membrane cofactor protein (MCP) consists of four alternatively spliced isoforms that coexist on most cells. The extracellular domain is composed of four control protein modules (CCPs). Western blot, flow cytometry, cell surface labeling, and pulse-chase analysis all showed that the mutant protein was retained intracellularly. Noris et al. described a family in which two siblings were affected by HUS. Mutation screening in both revealed a heterozygous 2-bp deletion in MCP exon 7, which encodes CCP4. The functional effect of this mutation is similar to the deletion mutation and results in half of the normal level of cell surface expression of MCP. The two techniques most frequently used for mutation scanning are denaturing high-performance liquid chromatography (DHPLC) and single-strand conformation polymorphism (SSCP). DHPLC is based on heteroduplex analysis in which mutant and wild-type sequences present in a PCR product are heated and allowed to reanneal slowly. This results in the formation of two heteroduplexes and two homoduplexes. MLPA (multiplex ligationdependent probe amplification) is a relatively new method for detecting deletions and duplications in a simple two-stage procedure and gives dosage information for up to 45 exons in one test.

Citation: Strain L, Goodship J, Goodship* T. 2006. Molecular and Clinical Evaluation of Atypical Hemolytic Uremic Syndrome, p 118-123. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch13
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Factor H mutations associated with HUS are identified above the corresponding CCP. (A) Missense mutations with normal factor H levels. (B) Mutations associated with factor H deficiency (Fr, frameshift; X, premature stop codon; Δ, deletion). The amino acid numbering includes the 18-amino-acid signal peptide.

Citation: Strain L, Goodship J, Goodship* T. 2006. Molecular and Clinical Evaluation of Atypical Hemolytic Uremic Syndrome, p 118-123. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch13
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Barilla-LaBarca, M. L.,, M. K. Liszewski,, J. D. Lambris,, D. Hourcade, and , J. P. Atkinson. 2002. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J. Immunol. 168: 62986304.
2. Berns, J. S.,, B. S. Kaplan,, R. C. Mackow, and , L. G. Hefter. 1992. Inherited hemolytic uremic syndrome in adults. Am. J. Kidney Dis. 19: 331334.
3. Buddies, M. R.,, R. L. Donne,, A. Richards,, J. Goodship, and , T. H. Goodship. 2000. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 66: 17211722.
4. Caprioli, J.,, P. Bettinaglio,, P. F. Zipfel,, B. Amadei,, E. Daina,, S. Gamba,, C. Skerka,, N. Marziliano,, G. Remuzzi, and , M. Noris. 2001. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 12: 297307.
5. Cole, J. L.,, G. A. Housley, Jr.,, T. R. Dykman,, R. P. MacDermott, and , J. P. Atkinson. 1985. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines. Proc. Natl. Acad. Sci. USA 82: 859863.
6. Devaux, P.,, D. Christiansen,, M. Fontaine, and , D. Gerlier. 1999. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation. Eur. J. Immunol. 29: 815822.
7. Dragon-Durey, M. A.,, V. Fremeaux-Bacchi,, C. Loirat,, J. Blouin,, P. Niaudet,, G. Deschenes,, P. Coppo,, F. W. Herman, and , L. Weiss. 2004. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 15: 787795.
8. Endoh, M.,, M. Yamashina,, H. Ohi,, K. Funahashi,, T. Ikuno,, T. Yasugi,, J. P. Atkinson, and , H. Okada. 1993. Immunohistochemical demonstration of membrane cofactor protein (MCP) of complement in normal and diseased kidney tissues. Clin. Exp. Immunol. 94: 182188.
9. Fremeaux-Bacchi, V.,, M. Dragon-Durey,, J. Blouin,, C. Vigneau,, D. Kuypers,, B. Boudailliez,, C. Loirat,, E. Rondeau, and , W. Fridman. 2004. Complement Factor I: a susceptibility gene for atypical hemolyticuremic syndrome. J. Med. Genet. 41: e84.
10. Ichida, S.,, Y. Yuzawa,, H. Okada,, K. Yoshioka, and , S. Matsuo. 1994. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int. 46: 8996.
11. Johnstone, R. W.,, B. E. Loveland, and , I. F. McKenzie. 1993. Identification and quantification of complement regulator CD46 on normal human tissues. Immunology 79: 341347.
12. Kaplan, B. S.,, R. W. Chesney, and , K. N. Drummond. 1975. Hemolytic uremic syndrome in families. N. Engl. J. Med. 292: 10901093.
13. Kaplan, B. S., and , P. Kaplan. 1992. Hemolytic uremic syndrome in families, p. 213225. In B. S. Kaplan,, R. S. Trompeter, and , J. L. Moake (ed.), Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Marcel Dekker, New York, N.Y.
14. Kirkitadze, M. D., and , P. N. Barlow. 2001. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol. Rev. 180: 146161.
15. Kojima, A.,, K. Iwata,, T. Seya,, M. Matsumoto,, H. Ariga,, J. P. Atkinson, and , S. Nagasawa. 1993. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J. Immunol. 151: 15191527.
16. Liszewski, M. K.,, T. C. Farries,, D. M. Lublin,, I. A. Rooney, and , J. P. Atkinson. 1996. Control of the complement system. Adv. Immunol. 61: 201283.
17. Manuelian, T.,, J. Hellwage,, S. Meri,, J. Caprioli,, M. Noris,, S. Heinen,, M. Jozsi,, H. P. Neumann,, G. Remuzzi, and , P. F. Zipfel. 2003. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111: 11811190.
18. McNearney, T.,, L. Ballard,, T. Seya, and , J. P. Atkinson. 1989. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. J. Clin. Invest. 84: 538545.
19. Moake, J. L. 2002. Thrombotic microangiopathies. N. Engl. J. Med. 347: 589600.
20. Nakanishi, I.,, A. Moutabarrik,, T. Hara,, M. Hatanaka,, T. Hayashi,, T. Syouji,, N. Okada,, E. Kitamura,, Y. Tsubakihara,, M. Matsumoto, et al. 1994. Identification and characterization of membrane cofactor protein (CD46) in the human kidneys. Eur. J. Immunol. 24: 15291535.
21. Neumann, H. P.,, M. Salzmann,, B. Bohnert-Iwan,, T. Mannuelian,, C. Skerka,, D. Lenk,, B. U. Bender,, M. Cybulla,, P. Riegler,, A. Konigsrainer,, U. Neyer,, A. Bock,, U. Widmer,, D. A. Male,, G. Franke, and , P. F. Zipfel. 2003. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J. Med. Genet. 40: 676681.
22. Noris, M.,, S. Brioschi,, J. Caprioli,, M. Todeschini,, E. Bresin,, F. Porrati,, S. Gamba, and , G. Remuzzi. 2003. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362: 15421547.
23. Oglesby, T. J.,, C. J. Allen,, M. K. Liszewski,, D. J. White, and , J. P. Atkinson. 1992. Membrane cofactor protein (CD46) protects cells from complement-mediated attack by an intrinsic mechanism. J. Exp. Med. 175: 15471551.
24. Ohali, M.,, H. Shalev,, M. Schlesinger,, Y. Katz,, L. Kachko,, R. Carmi,, S. Sofer, and , D. Landau. 1998. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr. Nephrol. 12: 619624.
25. Pangburn, M. K. 2002. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J. Immunol. 169: 47024706.
26. Pérez-Caballero, D.,, C. González-Rubio,, M. E. Gallardo,, M. Vera,, M. López Trascasa,, S. Rodríguez de Córdoba, and , P. Sánchez-Corral. 2001. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 68: 478484.
27. Perkins, S. J., and , T. H. J. Goodship. 2002. Molecular modelling of the C-terminal domains of factor H of human complement. A correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J. Mol. Biol. 316: 217224.
28. Pichette, V.,, S. Querin,, W. Schurch,, G. Brun,, G. Lehnernetsch, and , J. M. Delage. 1994. Familial hemolytic-uremic syndrome and homozygous factor-H deficiency. Am. J. Kidney Dis. 24: 936941.
29. Pirson, Y.,, C. Lefebvre,, C. Arnout, and , C. Van Ypersele de Strihou. 1987. Hemolytic uremic syndrome in three adult siblings: a family study and evolution. Clin. Nephrol. 28: 250255.
30. Post, T. W.,, M. K. Liszewski,, E. M. Adams,, I. Tedja,, E. A. Miller, and , J. P. Atkinson. 1991. Membrane cofactor protein of the complement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J. Exp. Med. 174: 93102.
31. Richards, A.,, M. R. Buddles,, R. L. Donne,, B. S. Kaplan,, E. Kirk,, M. C. Venning,, C. L. Tielemans,, J. A. Goodship, and , T. H. J. Goodship. 2001. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 68: 485490.
32. Richards, A.,, E. J. Kemp,, M. K. Liszewski,, J. A. Goodship,, A. K. Lampe,, R. Decorte,, M. H. Muslumanoglu,, S. Kavukcu,, G. Filler,, Y. Pirson,, L. S. Wen,, J. P. Atkinson, and , T. H. J. Goodship. 2003. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. USA 100: 1296612971.
33. Roodhooft, A. M.,, R. H. McLean,, E. Elst, and , K. J. Van Acker. 1990. Recurrent hemolytic uremic syndrome and acquired hypomorphic variant of the third component of complement. Pediatr. Nephrol. 4: 597599.
34. Russell, S. M.,, R. L. Sparrow,, I. F. McKenzie, and , D. F. Purcell. 1992. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur. J. Immunol. 22: 15131518.
35. Sanchez-Corral, P.,, D. Perez-Caballero,, O. Huarte,, A. M. Simckes,, E. Goicoechea,, M. Lopez-Trascasa, and , S. Rodriguez De Cordoba. 2002. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 71: 12851295.
36. Schouten, J. P.,, C. J. McElgunn,, R. Waaijer,, D. Zwijnenburg,, F. Diepvens, and , G. Pals. 2002. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30: e57.
37. Seya, T., and , J. P. Atkinson. 1989. Functional properties of membrane cofactor protein of complement. Biochem. J. 264: 581588.
38. Seya, T.,, J. R. Turner, and , J. P. Atkinson. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163: 837855.
39. Strachan, T., and , A. P. Read (ed.). 2003. Human Molecular Genetics, 3rd ed. Garland Science, London, United Kingdom.
40. Thompson, R. A., and , M. H. Winterborn. 1981. Hypocomplementaemia due to a genetic deficiency of beta-1H globulin. Clin. Exp. Immunol. 46: 110119.
41. Vyse, T. J.,, G. P. Bates,, M. J. Walport, and , B. J. Morley. 1994. The organization of the human complement factor I gene (IF): a member of the serine protease gene family. Genomics 24: 9098.
42. Vyse, T. J.,, B. J. Morley,, I. Bartok,, E. L. Theodoridis,, K. A. Davies,, A. D. Webster, and , M. J. Walport. 1996. The molecular basis of hereditary complement factor I deficiency. J. Clin. Invest. 97: 925933.
43. Vyse, T. J.,, P. J. Spath,, K. A. Davies,, B. J. Morley,, P. Philippe,, P. Athanassiou,, C. M. Giles, and , M. J. Walport. 1994. Hereditary complement factor I deficiency. Q. J. Med. 87: 385401.
44. Warwicker, P., and , T. H. J. Goodship. 2003. Haemolytic uraemic syndrome, p. 407410. In D. A. Warrell,, T. M. Cox,, J. D. Firth, and , E. J. Benz, Jr. (ed.), Oxford Textbook of Medicine. Oxford University Press, Oxford, United Kingdom.
45. Warwicker, P.,, T. H. J. Goodship,, R. L. Donne,, Y. Pirson,, A. Nicholls,, R. M. Ward, and , J. A. Goodship. 1998. Genetic studies into inherited and sporadic haemolytic uraemic syndrome. Kidney Int. 53: 836844.
46. Ying, L.,, Y. Katz,, M. Schlesinger,, R. Carmi,, H. Shalev,, N. Haider,, G. Beck,, V. C. Sheffield, and , D. Landau. 1999. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 65: 15381546.
47. Zipfel, P. F.,, T. S. Jokiranta,, J. Hellwage,, V. Koistinen, and , S. Meri. 1999. The factor H protein family. Immunopharmacology 42: 5360.


Generic image for table

Methods for mutation detection

Citation: Strain L, Goodship J, Goodship* T. 2006. Molecular and Clinical Evaluation of Atypical Hemolytic Uremic Syndrome, p 118-123. In Detrick B, Hamilton R, Folds J (ed), Manual of Molecular and Clinical Laboratory Immunology, 7th Edition. ASM Press, Washington, DC. doi: 10.1128/9781555815905.ch13

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error